Merck & Co., Inc. (MRK)

73.19
NYSE
Prev Close 73.19
Day Low/High 0.00 / 0.00
52 Wk Low/High 56.26 / 83.85
Exchange NYSE
Shares Outstanding 2583.07B
Market Cap 189.06B
Div & Yield N.A. (N.A)
Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #8 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #90 spot out of 500.

Results Of Phase 3 Trial Evaluating Merck's ZERBAXA® (ceftolozane And Tazobactam) Versus Meropenem For Treatment Of Adult Patients With Ventilated Nosocomial Pneumonia (VNP) To Be Presented At ECCMID 2019

Results Of Phase 3 Trial Evaluating Merck's ZERBAXA® (ceftolozane And Tazobactam) Versus Meropenem For Treatment Of Adult Patients With Ventilated Nosocomial Pneumonia (VNP) To Be Presented At ECCMID 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA ®...

FDA Approves Expanded Monotherapy Label For Merck's KEYTRUDA® (pembrolizumab)

FDA Approves Expanded Monotherapy Label For Merck's KEYTRUDA® (pembrolizumab)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

LYNPARZA® (olaparib) Approved In EU For The Treatment Of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

LYNPARZA® (olaparib) Approved In EU For The Treatment Of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has approved LYNPARZA as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (g BRCAm), and who...

Merck Completes Tender Offer To Acquire Immune Design

Merck Completes Tender Offer To Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Immune Design (NASDAQ: IMDZ) at a purchase price...

Merck To Hold First-Quarter 2019 Sales And Earnings Conference Call On April 30

Merck To Hold First-Quarter 2019 Sales And Earnings Conference Call On April 30

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Merck Completes Acquisition Of Antelliq Corporation To Become Leader In Emerging Digital Technology For Livestock And Companion Animals

Merck Completes Acquisition Of Antelliq Corporation To Become Leader In Emerging Digital Technology For Livestock And Companion Animals

Merck [NYSE:MRK], known as MSD outside the United States and Canada, today announced the completion of its acquisition of Antelliq Corporation from funds advised by BC Partners.

Dow Posts Solid Gains on Surge in China Manufacturing Output

Dow Posts Solid Gains on Surge in China Manufacturing Output

Stocks are higher Monday on a strong manufacturing report from China and indications of progress in the U.S.-China trade talks.

Merck Shares Gain After Lung Cancer Drug Keytruda Approved for Sale In China

Merck Shares Gain After Lung Cancer Drug Keytruda Approved for Sale In China

Merck shares edged higher Monday after the drugmaker won approval for the sale of its blockbuster lung cancer treatment in China.

Data For Merck's KEYTRUDA® (pembrolizumab) Across Different Types Of Advanced Lung Cancer Presented At AACR Annual Meeting 2019

Data For Merck's KEYTRUDA® (pembrolizumab) Across Different Types Of Advanced Lung Cancer Presented At AACR Annual Meeting 2019

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of results from a post-hoc analysis of patients with liver or brain metastases from the Phase 3 KEYNOTE-189 trial.

Merck's KEYTRUDA® (pembrolizumab) Approved In China For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) In Combination With Chemotherapy

Merck's KEYTRUDA® (pembrolizumab) Approved In China For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) In Combination With Chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in combination with pemetrexed and platinum...

Selumetinib Granted U.S. Breakthrough Therapy Designation In Neurofibromatosis Type 1

Selumetinib Granted U.S. Breakthrough Therapy Designation In Neurofibromatosis Type 1

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca shares traded near the bottom of the London market Friday after the drugmaker agreed a potential $6.9 billion deal with Japan's Daiichi Sankyo Co. to develop and market a breast and gastric cancer treatment over the coming years.

S&P 500 Returned a Record $1.26 Trillion in 2018 as Buybacks Topped $806 Billion

S&P 500 Returned a Record $1.26 Trillion in 2018 as Buybacks Topped $806 Billion

U.S.-listed stocks returned more than $1.2 trillion to investors last year, according to data published Monday by S&P Dow Jones Indices, with companies buying back a record $806.4 billion in shares thanks in part to a corporate tax windfall and a sharp market pullback in the final three months of the year.

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Jim Cramer says there's so much money being run by computers, stocks are virtually destined to come down in this situation. Here's the game plan.

Axon Enterprise, Perrigo, Merck: 'Mad Money' Lightning Round

Axon Enterprise, Perrigo, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Axon Enterprise, Perrigo, Merck, Alteryx, Enterprise Products Partners and more.

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Merck And NGM Bio Announce Extension Of Broad, Multi-Year Strategic Collaboration To 2022

Merck And NGM Bio Announce Extension Of Broad, Multi-Year Strategic Collaboration To 2022

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc.

New Treatment Option Now Available In Canada For Newly Diagnosed Patients With Advanced Lung Cancer

New Treatment Option Now Available In Canada For Newly Diagnosed Patients With Advanced Lung Cancer

KEYTRUDA ® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared to Chemotherapy Alone Every day, approximately 78 Canadians are diagnosed with lung cancer and 58 die from it i Non-small cell...

Digging Down on the Dow 30

Digging Down on the Dow 30

Just 13 of the 30 Dow components are in clear uptrends.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the...

Merck Becomes #3 Most Shorted Dow Stock, Replacing MMM

Merck Becomes #3 Most Shorted Dow Stock, Replacing MMM

The most recent short interest data has been released for the 02/28/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Why are big institutions running and can you outrace them?

Merck Prices $5.0 Billion Debt Offering

Merck Prices $5.0 Billion Debt Offering

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.

Merck Begins Tender Offer To Acquire Immune Design

Merck Begins Tender Offer To Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ).

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) For Six-Week Dosing Schedule Across All Current Monotherapy Indications

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) For Six-Week Dosing Schedule Across All Current Monotherapy Indications

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new extended dosing schedule for...

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of...

Merck Becomes #4 Most Shorted Dow Stock, Replacing Visa

Merck Becomes #4 Most Shorted Dow Stock, Replacing Visa

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: A- (Buy)